Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 1;221(1):8-15.
doi: 10.1093/infdis/jiz543.

Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season

Brendan Flannery  1 , Rebecca J Garten Kondor  1 , Jessie R Chung  1 , Manjusha Gaglani  2 , Michael Reis  2 , Richard K Zimmerman  3 , Mary Patricia Nowalk  3 , Michael L Jackson  4 , Lisa A Jackson  4 , Arnold S Monto  5 , Emily T Martin  5 , Edward A Belongia  6 , Huong Q McLean  6 , Sara S Kim  7 , Lenee Blanton  1 , Krista Kniss  1 , Alicia P Budd  1 , Lynnette Brammer  1 , Thomas J Stark  1 , John R Barnes  1 , David E Wentworth  1 , Alicia M Fry  1 , Manish Patel  1
Affiliations

Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season

Brendan Flannery et al. J Infect Dis. .

Abstract

Background: Increased illness due to antigenically drifted A(H3N2) clade 3C.3a influenza viruses prompted concerns about vaccine effectiveness (VE) and vaccine strain selection. We used US virologic surveillance and US Influenza Vaccine Effectiveness (Flu VE) Network data to evaluate consequences of this clade.

Methods: Distribution of influenza viruses was described using virologic surveillance data. The Flu VE Network enrolled ambulatory care patients aged ≥6 months with acute respiratory illness at 5 sites. Respiratory specimens were tested for influenza by means of reverse-transcriptase polymerase chain reaction and were sequenced. Using a test-negative design, we estimated VE, comparing the odds of influenza among vaccinated versus unvaccinated participants.

Results: During the 2018-2019 influenza season, A(H3N2) clade 3C.3a viruses caused an increasing proportion of influenza cases. Among 2763 Flu VE Network case patients, 1325 (48%) were infected with A(H1N1)pdm09 and 1350 (49%) with A(H3N2); clade 3C.3a accounted for 977 (93%) of 1054 sequenced A(H3N2) viruses. VE was 44% (95% confidence interval, 37%-51%) against A(H1N1)pdm09 and 9% (-4% to 20%) against A(H3N2); VE was 5% (-10% to 19%) against A(H3N2) clade 3C.3a viruses.

Conclusions: The predominance of A(H3N2) clade 3C.3a viruses during the latter part of the 2018-2019 season was associated with decreased VE, supporting the A(H3N2) vaccine component update for 2019-2020 northern hemisphere influenza vaccines.

Keywords: influenza; influenza vaccine; vaccine effectiveness.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Geographic distribution of influenza-positive tests (n = 43 330) identified by US public health laboratories during the 2018–2019 influenza season and A(H3N2)-positive specimens submitted to the Centers for Disease Control and Prevention for genetic characterization (n = 1093), by US Department of Health and Human Services surveillance region. A, B, Influenza viruses by type and subtype and genetic clades for A(H3N2) identified from 30 September 2018 through 2 February 2019. C, D, Influenza viruses and A(H3N2) clades identified from 3 February through 18 May 2019. Pie charts present proportional distribution of virus type or A subtype (A, C) or A(H3N2) genetic clade (B, D), based on the number of subtyped or genetically characterized influenza viruses from each region.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Wkly Epidemiol Rec 2019; 94:141–50.
    1. Process of influenza vaccine virus selection and development. http://apps.who.int/gb/pip/pdf_files/Fluvaccvirusselection.pdf. Accessed 17 April 2019.
    1. Recommended composition of influenza virus vaccines for use in the 2019- 2020 northern hemisphere influenza season 2019. https://www.who.int/influenza/vaccines/virus/recommendations/201902_reco.... Accessed 17 April 2019.
    1. Questions and answers: A(H3N2) component of the recommended composition of influenza virus vaccines for use in the northern hemisphere 2019–20 influenza season and development of candidate vaccine viruses for pandemic preparedness World Health Organization, 2019. https://www.who.int/influenza/vaccines/virus/recommendations/201902_qand.... Accessed 17 April 2019.
    1. Addendum to the recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season 2019. https://www.who.int/influenza/vaccines/virus/recommendations/201902_reco.... Accessed 17 April 2019.

Publication types

MeSH terms